



## **EHA2022 abstracts:** What's hot in lymphoma and CLL?

To help navigate the exciting content being presented at the EHA2022 Congress, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL.

A circular graphic with a white mouse cursor icon pointing towards the text.

**Click**  
the abstracts  
to view

This educational resource is supported through funds from pharmaceutical companies—a full list of our supporters can be found at <https://lymphomahub.com/>. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.

## Indolent and mantle cell NHL

S205	<a href="#"><u>Zanubrutinib + obinutuzumab (ZO) vs obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial</u></a>
S206	<a href="#"><u>Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: final analysis of the GALLIUM study</u></a>
S208	<a href="#"><u>Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma: primary analysis of the global phase 2 study TIDAL</u></a>
S209	<a href="#"><u>Primary results from the phase 3 SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle-cell lymphoma</u></a>

## Hodgkin lymphoma

S200	<a href="#"><u>Improved overall survival with first-line brentuximab vedotin plus chemotherapy in patients with stage III/IV classical Hodgkin lymphoma: 6-year analysis of ECHELON-1</u></a>
S201	<a href="#"><u>Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)</u></a>
S203	<a href="#"><u>Abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma: pre-planned interim analysis of the international GHSG phase II AERN trial</u></a>
S204	<a href="#"><u>Pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma with slow early response to frontline chemotherapy: The phase 2, open-label, KEYNOTE-667 study</u></a>

## T-cell lymphoma

S218	<a href="#"><u>A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T cell lymphoma</u></a>
------	--

## Aggressive B-NHL

LB2364	<a href="#"><u>Primary results of subcutaneous epcoritamab dose expansion in patients with relapsed or refractory large B-cell lymphoma: a phase 2 study</u></a>
LB2370	<a href="#"><u>R-CODOX-M/R-IVAC versus dose-adjusted(DA)-EPOCH-R in patients with newly diagnosed high-risk Burkitt lymphoma; first results of a multi-center randomized HOVON/SAKK trial</u></a>
P1190	<a href="#"><u>Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma from the POLARIX trial</u></a>
S211	<a href="#"><u>Clinical and patient-reported outcomes in a phase 3 study of axicabtagene ciloleucel (axi-cel) vs standard-of-care in elderly patients with relapsed/refractory large b-cell lymphoma (ZUMA-7)</u></a>
S212	<a href="#"><u>Phase I study of YTB323, a chimeric antigen receptor (CAR)-T cell therapy manufactured using T-Charge™, in patients with relapsed/refractory diffuse large B-cell lymphoma</u></a>
S220	<a href="#"><u>Glofitamab induces durable complete remissions and has favorable safety in patients with relapsed/refractory diffuse large B-cell lymphoma and ≥2 prior therapies: pivotal phase II expansion results</u></a>
S258	<a href="#"><u>Lisocabtagene maraleucel (liso-cel) as second-line therapy for R/R large B-cell lymphoma (LBCL) in patients not intended for HSCT: primary analysis from the phase 2 PILOT study</u></a>

## Chronic lymphocytic leukemia (CLL)

LB2365	<a href="#"><u>Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA/CLL13 trial</u></a>
S145	<a href="#"><u>The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: the results of the planned interim analysis of the phase III NCRI FLAIR trial</u></a>
S147	<a href="#"><u>Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study</u></a>
S148	<a href="#"><u>Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study</u></a>

## Advances in disease biology

P1284	<a href="#"><u>Liquid biopsy by ultra-deep sequencing plus PET-CT monitoring in real-life follicular lymphoma patients</u></a>
S101	<a href="#"><u>Genetic and epigenetic factors driving primary mediastinal B-cell lymphoma pathogenesis and outcome</u></a>
S143	<a href="#"><u>Transcriptomic characterization of MRD response and non-response in patients treated with fixed-duration venetoclax-obinutuzumab</u></a>
S225	<a href="#"><u>Circulating tumor DNA is a prognostic biomarker at baseline and improves the accuracy of interim PET in classic Hodgkin lymphoma</u></a>



Follow us on Twitter to keep up to date  
with the latest from the EHA2022  
Congress!

**@lymphomahub**  
**#EHA2022**  
**lymphomahub.com**